Friday, September 4, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 28, 2026

United States AI in Healthcare Market Forecast Report and Company Analysis 2025-2033 Featuring AWS, General Vision, Google, Intel, Medtronic, Micron, Microsoft, Next IT, NVIDIA, Siemens Healthcare

View original at finance.yahoo.com
United States AI in Healthcare Market Forecast Report and Company Analysis 2025-2033 Featuring AWS, General Vision, Google, Intel, Medtronic, Micron, Microsoft, Next IT, NVIDIA, Siemens Healthcare Company Logo The United States AI in Healthcare Market is projected to soar from US$ 10.26 billion in 2025 to US$ 99.77 bil…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Rapid digital transformation, growing demand for precision medicine, robust government support, and the need for affordable healthcare solutions are the main factors propelling the U.S. AI in healthcare market.

    80% confidence
  • Many small and mid-sized hospitals struggle to afford AI technologies, leading to uneven adoption across regions.

    80% confidence
  • NLP advancements are accelerating AI adoption across the U.S. healthcare sector by transforming how unstructured clinical data is utilized.

    80% confidence
  • California, Texas, New York, and Florida lead in AI healthcare adoption, bolstering U.S. AI healthcare innovation.

    80% confidence
  • The high cost of implementing AI technologies and the shortage of skilled professionals pose significant barriers to market growth.

    80% confidence
  • The United States AI in Healthcare Market is expected to reach US$ 99.77 billion by 2033 from US$ 10.26 billion in 2025, with a CAGR of 32.88% from 2025 to 2033.

    80% confidence
  • The United States is becoming a global leader in healthcare innovation as a result of the acceleration of AI integration brought about by rising healthcare costs and the expansion of big data availability.

    80% confidence
  • The FDA's support for AI-based medical devices and government programs encouraging healthcare digitization further accelerate industry growth.

    80% confidence
  • AI-powered precision medicine platforms are being deployed across oncology, neurology, and cardiology to identify molecular markers and optimize care delivery.

    80% confidence
  • One of the major challenges in the U.S. AI in Healthcare market is ensuring data privacy and compliance with complex regulations such as HIPAA and emerging state-specific laws.

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com